Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Potter

Physician Assistant Plano, TX Physician Assistant

NPI 1437190543 CMS profile 10866131

4708 Alliance Blvd Ste 150, Plano, TX 75093

Open in the dashboard

General payments

$7,765

283 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Potter of Plano, TX is reported in the CMS Open Payments database as having received $7,765 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,276 108
2024 General $3,607 100
2023 General $1,016 48
2022 General $829 26
2021 General $36 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Potter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jennifer Potter were reported at $2,276. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jennifer Potter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $36 $132 $37–$438 $132
2022 $829 $155 $48–$522 $149
2023 $1,016 $167 $52–$557 $160
2024 $3,607 $178 $55–$600 $164
2025 $2,276 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Incyte Corporation $1,962 9 payments
  2. Novartis Pharmaceuticals Corporation $672 39 payments
  3. Pfizer Inc. $458 21 payments
  4. Daiichi Sankyo Inc. $392 16 payments
  5. AstraZeneca Pharmaceuticals LP $317 13 payments
  6. Gilead Sciences, Inc. $312 17 payments
  7. Merck Sharp & Dohme Corporation $299 17 payments
  8. Janssen Biotech, Inc. $283 15 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $218 8 payments
  10. Pharmacyclics LLC, An AbbVie Company $197 5 payments
  11. Other $2,654 123 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,785 277 payments
  2. Consulting Fee $1,540 1 payment
  3. Education $440 5 payments
Products named General payments · program years 2021–2025
  1. ENHERTU $320 12 payments
  2. KEYTRUDA $299 17 payments
  3. IMBRUVICA $246 7 payments
  4. IBRANCE $197 7 payments
  5. TUKYSA $194 8 payments
  6. KISQALI $191 10 payments
  7. Trodelvy $185 11 payments
  8. SCEMBLIX $173 10 payments
  9. JAKAFI $170 3 payments
  10. INLYTA $153 8 payments
  11. Other $4,606 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

598

Median for Physician Assistant: 241

Drug cost

$164,943

Median for Physician Assistant: $4,110

Branded share of claims

8.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tasigna Nilotinib Hcl Brand 12 $157,767
Anastrozole Generic 89 $1,712
Tamoxifen Citrate Generic 21 $821
Potassium Chloride Generic 21 $750
Doxycycline Monohydrate Generic 21 $558
Letrozole Generic 42 $408
Dexamethasone Generic 28 $327
Oxybutynin Chloride Generic 15 $279
Acyclovir Generic 35 $261
Gabapentin Generic 34 $249

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$111,701

Medicare's payments for the services billed

Medicare patients

555

Average age 76

Services billed

5,219

371 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 51%
Arthritis 47%
Ischemic heart disease 37%
Chronic kidney disease 32%
Diabetes 25%
Depression 25%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 56 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $184
  • AstraZeneca Pharmaceuticals LP $53
$237 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $85
$85 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $80
$80 — —
SCEMBLIX
  • Novartis Pharmaceuticals Corporation $72
$72 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 56 with Patron

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record